For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Plerixafor + Chemo and G-CSF | Patients who receive a combination of Plerixafor, chemotherapy and G-CSF. Plerixafor : 240 µg/kg subcutaneous injection on the day that the ANC is \> 1500/mm3 and on each day of apheresis for a total of 4 aphereses or the target CD34 cell dose has been reached. | None | None | 0 | 45 | 29 | 45 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Nausea | None | Gastrointestinal disorders | None | View |
| Bone Pain | None | Musculoskeletal and connective tissue disorders | None | View |
| Diarrhea | None | Gastrointestinal disorders | None | View |
| Fatigue | None | General disorders | None | View |
| Hypokalemia | None | Blood and lymphatic system disorders | None | View |
| Lightheadedness | None | General disorders | None | View |
| Headache | None | General disorders | None | View |
| Thrombocytopenia Grade 1/2 | None | Blood and lymphatic system disorders | None | View |
| Thrombocytopenia Over Grade 2 | None | Blood and lymphatic system disorders | None | View |
| Anemia | None | Blood and lymphatic system disorders | None | View |